-
#ASH18 vs#ASH19... still haven’t gotten any taller!pic.twitter.com/7IYeSU6hWI
-
-
It was a very great opportunity and experience to present my Ph.D. project at
#ASH18. Thank you to@ASH_hematology &@nih_nhlbipic.twitter.com/nOVgFBaEEU – mjesto: San Diego Convention Center
-
The results of the PAUSE study on periop management of patients on DOACs (abstract at
#ASH18) has officially been published today in@JAMAInternalMed ! "Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant"https://ja.ma/2TcwQPp -
My frank thoughts on the MAIA trial in myeloma published in
@ASCOPost@ASCO#ASH18 Standard of care? No, not so fast. http://ascopost.com/issues/december-25-2018/epov-kenneth-shain-and-vincent-rajkumar/ …@mtmdphd@MyelomaTeacher@NorthTxMSG@BldCancerDoc@SagarLonialMDpic.twitter.com/xQaamvjV47
-
I’m excited and honored to receive a 2019 Junior Faculty Scholar Award from the American Society of Hematology. Feeling inspired by all the great research I saw a week ago at
#ASH18. http://www.hematology.org/Newsroom/Press-Releases/2018/9206.aspx … -
Energized after
#ASH18,@MullallyLab is recruiting postdocs to join our team!https://twitter.com/BrighamHeme/status/1069371406163431424 …
-
.
@aakonc discusses the results of a new study that showed oral anticoagulants are effective at preventing blood clots in high-risk cancer patients.#ASH18 pic.twitter.com/QyKZy7KWCR -
BCMA Day: At
#ASH18, Cell Therapies For Myeloma Take Center Stage https://xconomy.com/national/2018/12/04/bcma-day-at-ash-18-cell-therapies-for-myeloma-take-center-stage/ …$BLUE$CELG$JNJ$AMGN@PoseidaThera -
Come see my poster on contributions from low and middle-income countries to
#ASH18 later today! #2123 will be giving high fives for free
#ASH19pic.twitter.com/5B3KeG5CvQ
-
Drs. Lamanna, Friedberg and myself discussing the advances made in CLL at
#ASH18. It was a BIG year! Lot's to discuss.@sloan_kettering@Columbia@WilmotCancerpic.twitter.com/jZUQWSjp6b
-
For the first time, researchers have found an association between the makeup of the microorganisms in the body before a bone marrow transplant and a patient’s survival afterward.
#ASH18 http://bit.ly/2QJ7SbN -
Check out ASH Summary from Drs. Durie, Mikhael & Mateos and the
@IMFMyeloma#myeloma Patient Team https://shoutout.wix.com/so/97MU2TPhh#ASH18#IMFASH18 -
#ASH18 late breaking abstract showed newly FDA approved Emapalumab for#HLHpic.twitter.com/KmU8wffu1J
-
The latest ep of our biotech podcast is out! On the docket this week:
$MRNA tries to make biotech IPO history
#ASH18 and the quest to cure sickle cell disease
@megkesh on$CPRX's drug approval dreaded by patientshttps://www.statnews.com/2018/12/06/podcast-sickle-cell-ash-moderna-ipo/ … -
“#ASH18 - Part 6/6” Tweet collection, thanks to@DrMiguelPerales@ninashah33@hemedoc@AGP_hematology@JacobPlieth@graham74GC@chanyooncheah@drrdean@MyelomaTeacher@PilarNavaParada@drjgauthier@ByMadeleineA@AndyKinley & co for the share!https://twitter.com/i/moments/1069874354824056832 … -
It was great to see the results of the PAUSE trial that was presented at
#ASH18 about surgery in patients on#DOACs undergoing surgery or procedures. Temporary discontinuation is safe and effective with no bridging needed. Confirms our clinical practice.https://bit.ly/2SzMYsF -
No Len? No prob! CD98hc as a potential target in IMiD resistant MM. turns out Len targets CRBN to inhibit it’s function as a co-chaperone of HSP90
#mmsm#ASH18 pic.twitter.com/qyxL85QIxf
-
After
#ASH18, so looking forward to present our#patient survey#poster at#BSH2019 to this audience, as topic is "Assessing the needs for support for#mds patients in UK". Keen to see how we can cooperate with clinicians even more to further improve provision of info + supportpic.twitter.com/QOwaxKD3pa
Prikaži ovu nit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
can’t get more silly,
from their checked bag
and carry it on, because their security scanners can’t handle the density (of the knowledge!
).